A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The transforming genes of oncogenic retroviruses are homologous to a group of evolutionary conserved cellular onc genes. The human cellular homologue (c-abl) of the transforming sequence of Abelson murine leukaemia virus (A-MuL V) was recently shown to be located on chromosome 9. The long arm of this chromosome is involved in a specific translocation with chromosome 22, the Philadelphia translocation (Ph1), t(9; 22) (q34, q11), which occurs in patients with chronic myelocytic leukaemia (CML)3-5. Here we investigate whether the c-abl gene is included in this translocation. Using c-abl and v-abl hybridization probes on blots of somatic cell hybrids, positive hybridization is found when the 22q- (the Philadelphia chromosome), and not the 9q+ derivative of the translocation, is present in the cell hybrids. From this we conclude that in CML, c-abl sequences are translocated from chromosome 9 to chromosome 22q-. This finding is a direct demonstration of a reciprocal exchange between the two chromosomes and suggests a role for the c-abl gene in the generation of CML.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The importance of proto-oncogenes was further highlighted by discoveries that nonviral cancers frequently have genetic alterations in proto-oncogenes that activate them and drive oncogenesis—for example, mutations in H-ras or K-ras (76), gene amplification of c-myc (77), and chromosomal translocation/activation involving c-abl (78).”
From The Discovery of Reverse Transcriptase (2016) · cites this paper as [78]
Citations
Cites
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene
Parada, L. F., Tabin, C. J., Shih, C., & Weinberg, R. A. (1982) · Nature · doi:10.1038/297474a0 · Cited by 944
Der, C. J., Krontiris, T. G., & Cooper, G. M. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.11.3637 · Cited by 800
A physical map of the DNA regions flanking the rabbit β-globin gene
Jeffreys, A. (1977) · Cell · doi:10.1016/0092-8674(77)90119-2 · Cited by 644
Santos, E., Tronick, S. R., Aaronson, S. A., Pulciani, S., & Barbacid, M. (1982) · Nature · doi:10.1038/298343a0 · Cited by 623
Chang, E. H., Furth, M. E., Scolnick, E. M., & Lowy, D. R. (1982) · Nature · doi:10.1038/297479a0 · Cited by 587
Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine
Witte, O. N., Dasgupta, A., & Baltimore, D. (1980) · Nature · doi:10.1038/283826a0 · Cited by 530
Goff, S. P., Gilboa, E., Witte, O. N., & Baltimore, D. (1980) · Cell · doi:10.1016/0092-8674(80)90554-1 · Cited by 470
Khan, P. M. (1971) · Archives of Biochemistry and Biophysics · doi:10.1016/s0003-9861(71)80007-3 · Cited by 344
Chromosomal localization of human cellular homologues of two viral oncogenes
Heisterkamp, N., Groffen, J., Stephenson, J. R., Spurr, N. K., Goodfellow, P. N., Solomon, E., Carritt, B., & Bodmer, W. F. (1982) · Nature · doi:10.1038/299747a0 · Cited by 303
Self-citation
Research works printed but not linked: 2
- Heisterkamp, N., Groffen, J. & Stephenson, J. R. J. molec. appl. Genet. (in the press).
- Ferguson-Smith, M. A. & Aitken, D. A. Cytogenet. Cell Genet. 22, 49–451 (1978).
Cited by
Items 701–800 of 1,000
Raskind, W. H., Distèche, C. M., Keating, A., & Singer, J. W. (1987) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(87)90188-9 · Cited by 17
Genetic and cytogenetic changes in acute lymphoblastic leukemia
Ahuja, H. G., & Cline, M. J. (1988) · Medical Oncology and Tumor Pharmacotherapy · doi:10.1007/bf03003187 · Cited by 17
Multi-UnitAnti-BCR-ABLRibozyme Therapy in Chronic Myelogenous Leukemia
Leopold, L. H., Shore, S. K., & Reddy, E. P. (1996) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199609054774 · Cited by 17
Localization of the oncogene c‐erbA2 to human chromosome 3
Rider, S. H., Gorman, P. A., SHIPLEY, J. M., Moore, G. E., Vennström, B., Solomon, E., & Sheer, D. (1987) · Annals of Human Genetics · doi:10.1111/j.1469-1809.1987.tb01057.x · Cited by 17
Andreeff, M., Redner, A., Thongprasert, S., Eagle, B., Steinherz, P. G., Miller, D., & Melamed, M. R. (1985) · Springer eBooks · doi:10.1007/978-3-642-70458-1_10 · Cited by 17
The Philadelphia chromosome and Philadelphia chromosome mosaicism in chronic granulocytic leukemia.
Sokal, J. E., & Gómez, G. A. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.1.104 · Cited by 17
Wang, Y., Wang, X., Huang, X., Zhang, J., Hu, J., Qi, Y., Xiang, B., & Wang, Q. (2021) · Journal of Cancer · doi:10.7150/jca.56005 · Cited by 18
“Among them, ABL1 is a protooncogene that encodes a protein tyrosine kinase involved in a variety of cellular processes [68, 69].”
BackgroundTyrosine kinase inhibitors in cancers: Treatment optimization – Part I
Combarel, D., Dousset, L., Bouchet, S., Ferrer, F., Tétu, P., Lebbé, C., Ciccolini, J., Meyer, N., & Paci, A. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104384 · Cited by 18
Lymphoid malignancies: Another face to the Janus kinases
Scott, L. M. (2013) · Blood Reviews · doi:10.1016/j.blre.2012.12.004 · Cited by 16
Clinically relevant cancer biomarkers and pharmacogenetic assays
Patel, J. N., Mandock, K., & McLeod, H. L. (2013) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155212473862 · Cited by 17
Role of chimeric transcript formation in the pathogenesis of birth defects
Yamada, M., Suzuki, H., Watanabe, A., Uehara, T., Takenouchi, T., Mizuno, S., & Kosaki, K. (2020) · Congenital Anomalies · doi:10.1111/cga.12400 · Cited by 16
Song, T., Chai, G., Liu, Y., Xie, M., Chen, Q., Yu, X., Sheng, H., & Zhang, Z. (2015) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2015.01.003 · Cited by 18
Targeting β-catenin in CML: Leukemia Stem Cells Beware!
Kleppe, M., & Levine, R. L. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.03.006 · Cited by 16
“The discovery of a constitutively active BCRABL tyrosine kinase, which is generated from the reciprocal translocation of chromosomes 9 and 22 (de Klein et al., 1982), as the causative lesion in CML led to the development of the first tyrosine kinase inhibitor (TKI) for targeted therapy of human…”
BackgroundMultiplex Fluorescent RT-PCR to Quantify Leukemic Fusion Transcripts
Dupont, M., Goldsborough, A. S., Levayer, T., Savare, J., Rey, J.-M., Rossi, J., DEMAILLE, J. G., & Lavabre‐Bertrand, T. (2002) · BioTechniques · doi:10.2144/02331md04 · Cited by 16
Valent, P. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02328.x · Cited by 18
Selective deletion of exon 1β of thep19ARF gene in metastatic melanoma cell lines
Kumar, R., Sauroja, I., Punnonen, K. R. A., Jansén, C. T., & Hemminki, K. (1998) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199811)23:3<273::aid-gcc11>3.0.co;2-n · Cited by 82
The Molecular Biology of CML: A Review
Leibowitz, D. S., Young, K., Band, P. R., Deschamps, M., & Israël, L. (1989) · Cancer Investigation · doi:10.3109/07357908909038285 · Cited by 16
Dylla, S. J., Deyle, D. R., Theunissen, K., Padurean, A. M., & Verfaillie, C. M. (2004) · Experimental Hematology · doi:10.1016/j.exphem.2004.01.001 · Cited by 16
Philadelphia chromosome-positive leukaemia: the translocated genes and their gene products
Allen, P. B., Morgan, G. J., & Wiedemann, L. M. (1992) · Baillière s Clinical Haematology · doi:10.1016/s0950-3536(11)80051-x · Cited by 16
DIFFERENT ALLELIC PATTERNS AT CHROMOSOME 11q13 IN PAIRED ALDOSTERONE‐PRODUCING TUMOURS AND BLOOD DNA
Gordon, R. D., Gartside, M. G., Tunny, T. J., & Stowasser, M. (1996) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1996.tb02790.x · Cited by 16
Seong, D., Thall, P. F., Kantarjian, H. M., Talpaz, M., Swantkowski, J., Xu, J., Shen, Y., Glassman, A., Ramagli, L. S., & Siciliano, M. (1998) · PubMed · Cited by 16
Popescu, N. C., Amsbaugh, S. C., Milo, G., & DiPaolo, J. A. (1986) · PubMed · Cited by 16
Niederle, N., Moritz, T., Kloke, O., Wandl, U. B., May, D., Becher, R., Franz, T., Opalka, B., & Schmidt, C. G. (1991) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(91)90556-s · Cited by 16
Treatment of Chronic Myelogenous Leukemia with Recombinant Human Interleukin-2 and Interferon-α2a
Nagler, A., Ackerstein, A., Barak, V., & Slavin, S. (1994) · Journal of Hematotherapy · doi:10.1089/scd.1.1994.3.75 · Cited by 16
Jacquemin, P., Strijckmans, P., & Thiry, L. F. (1984) · Blood · doi:10.1182/blood.v64.4.832.832 · Cited by 16
A methyltransferase-independent role for METTL1 in tRNA aminoacylation and oncogenic transformation
Ali, R. H., Orellana, E. A., Lee, S. H., Chae, Y., Chen, Y., Clauwaert, J., Kennedy, A. L., Gutierrez, A., Papke, D. J., Valenzuela, M., et al. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.01.003 · Cited by 19
OCT-1 function varies with cell lineage but is not influenced by BCR-ABL
Engler, J., Zannettino, A. C. W., Bailey, C. G., Rasko, J. E. J., Hughes, T. P., & White, D. L. (2010) · Haematologica · doi:10.3324/haematol.2010.033290 · Cited by 15
“Chronic myeloid leukemia (CML) is a clonal myeloproliferative disease characterized by the reciprocal translocation between chromosomes 9 and 22, resulting in the formation of a constitutively active tyrosine kinase, BCRABL.(1,2) The resultant BCR-ABL oncoprotein is essential for chronic myeloid leukemia pathogenesis,…”
BackgroundDiagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update
Molica, M., Massaro, F., & Breccia, M. (2017) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2017.1383156 · Cited by 16
“[8] demonstrated that the translocation previously described, was reciprocal t(9;22) (q34;q11).”
BackgroundKuo, C., Wang, P., Hwang, W., Tzeng, C., Bai, L.-Y., Tang, J., Chang, M., Lin, S.-F., Chen, T., Chen, Y., et al. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718756603 · Cited by 15
Galli, S. J. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703 · Cited by 19
Leguay, T., & Mahon, F. (2005) · Encyclopédie médico-chirurgicale. Hématologie · doi:10.1016/j.emch.2005.07.001 · Cited by 34
Cytogenetic and Molecular Changes in Leukemia Found among Atomic Bomb Survivors
Kamada, N. (1991) · Journal of Radiation Research · doi:10.1269/jrr.32.supplement_172 · Cited by 15
Opalka, B., Wandl, U. B., Kloke, O., Beer, U., Seeber, S., & Niederle, N. (1992) · Leukemia Research · doi:10.1016/0145-2126(92)90039-a · Cited by 15
The human myoglobin gene: a third dispersed globin locus in the human genome
Jeffreys, A. J., Wilson, V., Blanchetot, A., Weller, P. A., van Kessel, A. G., Spurr, N. K., Solomon, E., & Goodfellow, P. N. (1984) · Nucleic Acids Research · doi:10.1093/nar/12.7.3235 · Cited by 15
Self-citationLuthra, R., & Medeiros, L. J. (2006) · Humana Press eBooks · doi:10.1385/1-59745-069-3:135 · Cited by 15
Okabe, T., Yoshida, E., Chieda, S., ENDO, K., Kamiya, S., OSADA, K., Tanaka, S., Okura, A., & Suda, H. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.289 · Cited by 15
Futaki, M., Inokuchi, K., Matsuoka, H., Miyake, K., Dan, K., & Nomura, T. (1992) · Leukemia Research · doi:10.1016/0145-2126(92)90045-9 · Cited by 15
Ohyashiki, J. H., Ohyashiki, K., Ito, H., & Toyama, K. (1988) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(88)90057-x · Cited by 15
Astrin, S. M., & Rothberg, P. G. (1983) · Cancer Investigation · doi:10.3109/07357908309063299 · Cited by 16
Denderen, J. V., van der Plas, D., Boer, T. M.-D., Zegers, N. D., Boersma, W. J. A., Grosveld, G. C., & van Ewijk, W. (1990) · Blood · doi:10.1182/blood.v76.1.136.136 · Cited by 15
Self-citationThe bcr‐c‐abl tyrosine kinase activity is extinguished by TPA in K562 leukemia cells
Alitalo, R. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)80389-7 · Cited by 15
Siracusa, L. D., & Abbott, C. M. (1991) · Mammalian Genome · doi:10.1007/bf00656484 · Cited by 16
Ko, J., Patel, N. K., Ikawa, T., Kawamoto, H., Frank, O., Rivera, R. R., Etten, R. A. V., & Murre, C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805073105 · Cited by 14
Zhao, Z.-G., Li, W., Chen, Z., You, Y., & Zou, P. (2008) · Cancer Investigation · doi:10.1080/07357900701788049 · Cited by 14
“It is characterized at cytogenetic level by the Philadelphia (Ph) chromosome and at the molecular level by the BCR/ABL gene rearrangement (18, 19).”
BackgroundBCR ABL KINASE INHIBITORS FOR CANCER THERAPY
Patel, D. T., Suthar, M. P., Patel, V. P., & Singh, R. (2010) · International Journal of Pharmaceutical Sciences and Drug Research · doi:10.25004/ijpsdr.2010.020201 · Cited by 14
“[1] In 1960, Nowell and Hungerford described a consistent”
BackgroundChronic Myeloid Leukemia — A Brief History
Goldman, J. M., & Daley, G. Q. (2007) · Springer eBooks · doi:10.1007/978-3-540-34506-0_1 · Cited by 14
“Of very great importance was the observation that it selectively inhibited in vitro the proliferation of myeloid progenitor cells taken from the blood of patents with Ph-positive CML while leaving relatively unaffected residual Ph-negative progenitors ( Deininger et al. 1997; Druker et al. 1996).”
BackgroundInfluentialBhatia, R., Munthe, H. A., & Forman, S. J. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03192.x · Cited by 14
“Malignant cells in CML are characterized by the 9;22 translocation leading to the formation of the BCR±ABL fusion oncogene (Rowley, 1973; DeKlein et al, 1982), which plays a critical role in the pathogenesis of CML (Daley et al, 1990; Pear et al, 1998).”
BackgroundFazeny-Dörner, B. (2003) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(03)00144-4 · Cited by 14
Gessler, M. (1988) · Genomics · doi:10.1016/0888-7543(88)90141-3 · Cited by 14
DNA Repair and Chromosomal Translocations
Bohlander, S. K., & Kakadia, P. M. (2015) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-20291-4_1 · Cited by 20
Oncogenes: A Review with Relevance to Cancers of the Urogenital Tract
Peehl, D. M., & Stamey, T. A. (1986) · The Journal of Urology · doi:10.1016/s0022-5347(17)45918-0 · Cited by 14
Jolicoeur, P., Villeneuve, L., Rassart, É., & Kozak, C. A. (1985) · Journal of Virology · doi:10.1128/jvi.56.3.1045-1048.1985 · Cited by 14
Role of the ABL oncogene tyrosine kinase activity in human leukaemia
Pendergast, A. M., & Witte, O. N. (1987) · Baillière s Clinical Haematology · doi:10.1016/s0950-3536(87)80036-7 · Cited by 14
Oncogenes, viruses, or rheumogenes?
Williams, R. C., Sibbitt, W. L., & Husby, G. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90656-x · Cited by 14
The use of recombinant DNA technology to study gene alteration
Mekler, P., Delehanty, J., Lohman, P. H. M., Brouwer, J., van de Putte, P., Pearson, P. L., Pouwels, P. H., & Ramel, C. (1985) · Mutation Research/Reviews in Genetic Toxicology · doi:10.1016/0165-1110(85)90004-1 · Cited by 14
Frassoni, F., Podestà, M., Piaggio, G., Rosti, V., Pitto, A., Benvenuto, F., Figari, O., Vassallo, F., Carella, A. M., Zikos, P., et al. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01201.x · Cited by 14
The Genes That Carcinogens Act Upon
Anderš, F., Schartl, M., Barnekow, A., Schmidt, C. R., Lüke, W., Jaenel-Dess, G., & Anders, A. (1985) · Hämatologie und Bluttransfusion · doi:10.1007/978-3-642-70385-0_51 · Cited by 14
Takeda, K., Ohta, S., Nagao, M., Kobayashi, E., Tago, K., & Funakoshi‐Tago, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073693 · Cited by 13
McKusick, V. A., & Harper, P. S. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-383834-6.00001-x · Cited by 15
Fujita, A., Shishido, T., Yuan, Y., Inamoto, E., Narumiya, S., & Watanabe, N. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.051706 · Cited by 13
“ABBREVIATIONS: CML, chronic myelogenous leukemia; STI571 [imatinib mesylate; Gleevec (US) or Glivec (Europe/Australia)], 4-[(4-methyl-1piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-phenyl]benzamide methanesulfonate; Abl, Abelson kinase; Bcr, breakpoint cluster region; EGFP, enhanced green fl…”
BackgroundInfluentialPredicting the Response of CML Patients to Tyrosine Kinase Inhibitor Therapy
White, D. L., & Hughes, T. P. (2011) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-011-0087-9 · Cited by 13
How to detect the rare BCR‑ABL (e14a3) transcript: A case report and literature review
Hu, L., Pu, L., Yang, D., Zhang, C., Wang, H., Ding, Y., Li, M., Zhai, Z., & Xiong, S. (2017) · Oncology Letters · doi:10.3892/ol.2017.6847 · Cited by 13
Quality Control Methods for Optimal BCR-ABL1 Clinical Testing in Human Whole Blood Samples
Stanoszek, L. M., Crawford, E. L., Blomquist, T. M., Warns, J. A., Willey, P., & Willey, J. C. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.02.004 · Cited by 13
Browett, P., Cooke, H. M., Secker‐Walker, L. M., & Norton, J. D. (1989) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(89)90046-0 · Cited by 13
Chronic myeloid leukemia with a rare variant Philadelphia translocation
Emberger, W., Behmel, A., Tschernigg, M., Seewann, H. L., Petek, E., Kroisel, P. M., & Wagner, K. (2001) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(01)00417-4 · Cited by 13
Oncogenes, Malignant Transformation, and Modern Medicine
Miller, D. M., Blume, S. W., Borst, M. P., Gee, J. E., Polansky, D. A., Ray, R. B., Rodu, B., Shrestha, K., Snyder, R., Thomas, S. D., et al. (1990) · The American Journal of the Medical Sciences · doi:10.1097/00000441-199007000-00013 · Cited by 13
Samassékou, O., Malina, A., Hébert, J., & Yan, J. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-26 · Cited by 14
The Biological Basis for Immunotherapy in Patients with Chronic Mye-logenous Leukemia
Pinilla-Ibarz, J. A., Shah, B. D., & Dubovsky, J. A. (2009) · Cancer Control · doi:10.1177/107327480901600206 · Cited by 13
Sessarego, M., Fugazza, G., Canepa, L., Bacigalupo, A. P., Bruzzone, R., & Patrone, F. (1995) · Leukemia Research · doi:10.1016/0145-2126(95)00093-3 · Cited by 13
Feedback Inhibitors in Normal and Tumor Tissues
Marshall, E., & Lord, B. I. (1996) · International review of cytology · doi:10.1016/s0074-7696(08)61348-0 · Cited by 13
Variant Philadelphia translocations in CML: Correlation with fragile sites
Sessarego, M., Defferrari, R., Panarello, C., Frassoni, F., Mandich, P., & Ajmar, F. (1988) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(88)90017-9 · Cited by 13
Yee, K. W. L., Anglin, P., & Keating, A. (1999) · Blood Reviews · doi:10.1016/s0268-960x(99)90016-4 · Cited by 14
Peters, K. L., & Smithgall, T. E. (1999) · Cellular Signalling · doi:10.1016/s0898-6568(99)00021-2 · Cited by 13
Deletion of BCR region 3′ in chronic myelogenous leukemia
González, F. A., Anguita, E., Mora, A., Asenjo, S., López, I., Polo, M., & Villegas, A. (2001) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(01)00469-1 · Cited by 13
Applications of recombinant DNA to pathologic diagnosis.
Sauls, C. D., & Caskey, C. T. (1985) · Clinical Chemistry · doi:10.1093/clinchem/31.6.804 · Cited by 14
Molecular biology of testicular germ cell tumors: current status
Schmidt, B., Ackermann, R., & Strohmeyer, T. G. (1995) · Journal of Molecular Medicine · doi:10.1007/bf00192887 · Cited by 13
Reiffers, Taylor, T., Gluckman, É., Gorin, Mahon, MiclÉa, DestrÉe, & Gautier (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00821.x · Cited by 13
“…myeloid leukaemia (CML) is an acquired clonal haemopoietic stem cell disorder characterized by the presence of a chromosomal marker, the Philadelphia (Ph) chromosome, which results from a reciprocal translocation t(9,22) (q34;q11) and is present in all cells of the clone (De Klein et al, 1982).”
BackgroundAUTOLOGOUS TRANSPLANTATION FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA
Bhatia, R., & Forman, S. J. (1998) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70501-3 · Cited by 13
Chronic myelogenous leukemia and genetic events at 9q34
Lewis, J. P., Watson‐Williams, E. J., Lazerson, J., & Jenks, H. M. (1983) · Hematological Oncology · doi:10.1002/hon.2900010309 · Cited by 13
Cancer incidence, survival, and mortality for children younger than age 15 years
Young, J. L., Ries, L. G., Silverberg, E., Horm, J. W., & Miller, R. W. (1986) · Cancer · doi:10.1002/1097-0142(19860715)58:2+<598::aid-cncr2820581332>3.0.co;2-c · Cited by 571
CLINICAL IMPLICATIONS OF CYTOGENETIC ABNORMALITIES IN MELANOMA
Nelson, M. A., Thompson, F. H., Emerson, J., Aickin, M. G., Adair, L., Trent, J. M., Leong, S. P. L., & Taetle, R. (1996) · Surgical Clinics of North America · doi:10.1016/s0039-6109(05)70513-2 · Cited by 13
Avner, P. R., Bućan, M., Arnaud, D., Lehrach, H. R., & Rapp, U. R. (1987) · Somatic Cell and Molecular Genetics · doi:10.1007/bf01535208 · Cited by 13
The Role of Molecular Genetics in Screening for Multiple Endocrine Neoplasia Type 1
Thakker, R. V. (1994) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30120-8 · Cited by 13
Overview of chronic myeloid leukemia patients in Pakistan in the pre-imatanib era.
Usmani, S. Z., Yunus, S., & Jamal, Y. (2009) · PubMed · Cited by 12
Leukaemias into the 21st century – part 2: the chronic leukaemias
Gibson, J., Iland, H. J., Larsen, S. R., Brown, C. M., & Joshua, D. E. (2013) · Internal Medicine Journal · doi:10.1111/imj.12135 · Cited by 12
Zhang, J.-H., He, Y., Zhu, R., Du, W. J., & Xiao, J. (2017) · Tumor Biology · doi:10.1177/1010428317713394 · Cited by 14
ABL1 and ABL2 promote medulloblastoma leptomeningeal dissemination
Jones, J. K., Zhang, H., Lyne, A.-M., Cavalli, F. M. G., Hassen, W. E., Stevenson, K., Kornahrens, R., Yang, Y., Li, S., Dell, S., et al. (2023) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdad095 · Cited by 13
Alternative Splicing in Chronic Myeloid Leukemia (CML): A Novel Therapeutic Target?
Adamia, S., Pilarski, P. M., Bar‐Natan, M., Stone, R. M., & Griffin, J. D. (2013) · Current Cancer Drug Targets · doi:10.2174/15680096113139990083 · Cited by 13
Campbell, M. L., Lu, D., Guo, J. Q., & Arlinghaus, R. B. (1993) · PubMed · Cited by 12
Expression and nature of the alkaline phosphatase gene in cultured osteosarcoma cells
Stinson, R. A., Thacker, J. D., & Lin, C. (1993) · Clinica Chimica Acta · doi:10.1016/0009-8981(93)90025-y · Cited by 12
Stopera, S. A., Ray, M., Riordan, D., Christie, N., & Wickstrom, D. E. (1990) · Cancer Letters · doi:10.1016/0304-3835(90)90126-i · Cited by 12
Emerging drugs in chronic myelogenous leukaemia
Bocchia, M., Forconi, F., & Lauria, F. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.4.651 · Cited by 13
“As such, Ph chromosome is sufficient for transformation and necessary for maintenance of CML [1].”
BackgroundInfluentialKovács, G., Georgii, A., & Mainzer, K. (1986) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(86)90104-4 · Cited by 12
Cytogenetic study in a mentally retarded child with bloom syndrome and acute lymphoblastic leukemia
Werner‐Favre, C., Wyss, M., Cabrol, C., Félix, F., Guenin, R., Laufer, D., & Engel, E. (1984) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320180205 · Cited by 12
Oncogenes and gastrointestinal cancer.
Forgács, I. (1988) · Gut · doi:10.1136/gut.29.4.417 · Cited by 15
The Evolving Role of Bone Marrow Transplantation in the Treatment of Chronic Myelogenous Leukemia
Delage, R., Ritz, J., & Anderson, K. C. (1990) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(18)30493-3 · Cited by 12
Freed, E., & Hunter, T. R. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.3.1312 · Cited by 12
FIRST TRIMESTER PRENATAL EXCLUSION OF TUBEROUS SCLEROSIS
Connor, J. M., Loughlin, S. A. R., & Whittle, M. J. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92722-x · Cited by 12
"Masked" Ph1 chromosome abnormalities in CML: a report of two unique cases
Bernstein, R., Pinto, M., Rosendorff, J., Kramer, S., & Mendelow, B. (1984) · Blood · doi:10.1182/blood.v63.2.399.399 · Cited by 12
Wang, J., Liang, Y., Qin, Y., Jiang, G., Peng, Y., & Feng, W. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03586-2 · Cited by 12
“Discussion BCR-ABL is a fusion gene that leads to the occurrence and progression of CML [2, 36].”
Background
Metadata
- Authors
- Klein, A. D., Kessel, A. G. V., Grosveld, G., Bartram, C. R., Hagemeijer, A., Bootsma, D., Spurr, N. K., Heisterkamp, N., Groffen, J., & Stephenson, J. R.
- Affiliations
- Erasmus University Rotterdam (NL)
- National Cancer Institute (US)
- Venue
- Nature
- Published
- 1982-12
- Volume
- 300
- Issue
- 5894
- Pages
- 765-767
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2060833726
- Cited by
- 1,378
- References
- 27
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 17 · 2023: 12 · 2022: 25 · 2021: 17 · 2020: 18 · 2019: 15 · 2018: 23 · 2017: 28 · 2016: 24 · 2015: 33 · 2014: 16 · 2013: 26 · 2012: 33
- FWCI
- 50.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
- Keywords
- Philadelphia chromosome, chromosome 9, chromosome 22, reciprocal translocation, cellular oncogenes, somatic cell hybrids
- MeSH terms
- Chromosomes, Human, 21-22 and Y, Chromosomes, Human, 6-12 and X, DNA, Neoplasm, Gene Expression Regulation, Humans, Leukemia, Myeloid, Oncogenes, Translocation, Genetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.